Doxa AB (publ) (DOXA.ST)
SEK 0.57
(4.63%)
SEK 0.57
(4.63%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 296 Million SEK | 71.68% |
| 2022 | -39.8 Million SEK | 14.11% |
| 2021 | 77.2 Million SEK | -166.61% |
| 2020 | -12.2 Million SEK | -19.83% |
| 2019 | -10.97 Million SEK | -204.75% |
| 2018 | 9.95 Million SEK | 216.37% |
| 2017 | -8.55 Million SEK | 8.35% |
| 2016 | -9.32 Million SEK | 39.42% |
| 2015 | -15.4 Million SEK | 11.41% |
| 2014 | -17.38 Million SEK | 7.25% |
| 2013 | -18.74 Million SEK | 20.63% |
| 2012 | -23.61 Million SEK | 49.66% |
| 2011 | -46.9 Million SEK | -60.91% |
| 2010 | -29.15 Million SEK | 8.03% |
| 2009 | -31.69 Million SEK | 22.8% |
| 2008 | -41.05 Million SEK | -6.73% |
| 2007 | -38.46 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 13.4 Million SEK | 104.2% |
| 2024 Q1 | 11.3 Million SEK | 31.07% |
| 2023 Q1 | -5.5 Million SEK | 3.51% |
| 2023 FY | - SEK | 71.68% |
| 2023 Q2 | -22.7 Million SEK | -312.73% |
| 2023 Q4 | 17.9 Million SEK | 752.38% |
| 2023 Q3 | 2.1 Million SEK | 109.25% |
| 2022 Q1 | -14 Million SEK | -115.52% |
| 2022 FY | - SEK | 14.11% |
| 2022 Q4 | -5.7 Million SEK | -23.91% |
| 2022 Q3 | -4.6 Million SEK | -6.98% |
| 2022 Q2 | -4.3 Million SEK | 69.29% |
| 2021 FY | - SEK | -166.61% |
| 2021 Q2 | -4 Million SEK | -53.85% |
| 2021 Q3 | -6.1 Million SEK | -52.5% |
| 2021 Q4 | 90.2 Million SEK | 1578.69% |
| 2021 Q1 | -2.6 Million SEK | -8.79% |
| 2020 Q1 | -2.6 Million SEK | -2013.82% |
| 2020 Q3 | -3.7 Million SEK | -0.27% |
| 2020 Q2 | -3.69 Million SEK | -41.92% |
| 2020 Q4 | -2.39 Million SEK | 35.41% |
| 2020 FY | - SEK | -19.83% |
| 2019 Q4 | -123 Thousand SEK | 98.27% |
| 2019 FY | - SEK | -204.75% |
| 2019 Q3 | -7.1 Million SEK | -373.33% |
| 2019 Q2 | -1.5 Million SEK | 16.67% |
| 2019 Q1 | -1.8 Million SEK | -33.33% |
| 2018 FY | - SEK | 216.37% |
| 2018 Q4 | -1.35 Million SEK | -12.5% |
| 2018 Q3 | -1.2 Million SEK | -107.84% |
| 2018 Q1 | -2.7 Million SEK | -671.43% |
| 2018 Q2 | 15.3 Million SEK | 666.67% |
| 2017 FY | - SEK | 8.35% |
| 2017 Q3 | -1.9 Million SEK | 44.12% |
| 2017 Q2 | -3.4 Million SEK | -6.25% |
| 2017 Q1 | -3.2 Million SEK | -10934.48% |
| 2017 Q4 | -350 Thousand SEK | 81.58% |
| 2016 Q3 | -2.7 Million SEK | 15.63% |
| 2016 Q2 | -3.2 Million SEK | 5.88% |
| 2016 Q4 | -29 Thousand SEK | 98.93% |
| 2016 FY | - SEK | 39.42% |
| 2016 Q1 | -3.4 Million SEK | 15.0% |
| 2015 FY | - SEK | 11.41% |
| 2015 Q4 | -4 Million SEK | -2.56% |
| 2015 Q3 | -3.9 Million SEK | -8.33% |
| 2015 Q2 | -3.6 Million SEK | 5.26% |
| 2015 Q1 | -3.8 Million SEK | -47.06% |
| 2014 Q3 | -3.2 Million SEK | 43.86% |
| 2014 Q1 | -5.9 Million SEK | -24.16% |
| 2014 Q2 | -5.7 Million SEK | 3.39% |
| 2014 Q4 | -2.58 Million SEK | 19.25% |
| 2014 FY | - SEK | 7.25% |
| 2013 Q4 | -4.75 Million SEK | -21.85% |
| 2013 Q1 | -5.1 Million SEK | 1.18% |
| 2013 FY | - SEK | 20.63% |
| 2013 Q3 | -3.9 Million SEK | 22.0% |
| 2013 Q2 | -5 Million SEK | 1.96% |
| 2012 Q4 | -5.16 Million SEK | 0.0% |
| 2012 FY | - SEK | 49.66% |
| 2011 FY | - SEK | -60.91% |
| 2010 FY | - SEK | 8.03% |
| 2009 FY | - SEK | 22.8% |
| 2008 FY | - SEK | -6.73% |
| 2007 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AddLife AB (publ) | 1.54 Billion SEK | 80.854% |
| Biotage AB (publ) | 432 Million SEK | 31.481% |
| Bonesupport Holding AB (publ) | 28.93 Million SEK | -922.912% |
| Elekta AB (publ) | 3.29 Billion SEK | 91.006% |
| iZafe Group AB (publ) | -15.61 Million SEK | 1995.37% |
| Ortivus AB (publ) | -14.92 Million SEK | 2083.117% |
| Ortivus AB (publ) | -14.92 Million SEK | 2083.117% |
| Q-linea AB (publ) | -210.98 Million SEK | 240.294% |
| S2Medical AB (publ) | -13.52 Million SEK | 2287.872% |
| Synsam AB (publ) | 1.71 Billion SEK | 82.7% |